                         SEQUENCE LISTING

<110>  The Regents of The University of California
 
<120>  Compositions, Devices, and Methods related to Prostate-Specific 
       Membrane Antigen

<130>  100843.0052PCT

<150>  US 61/179441
<151>  2009-05-19

<160>  13    

<170>  PatentIn version 3.4

<210>  1
<211>  8
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic oligopeptiide

<400>  1

Cys Ala Leu Cys Glu Phe Leu Gly 
1               5               


<210>  2
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic oligopeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is any amino acid, preferably an amino acid with a linear 
       side chain, most preferably serine or leucine

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is an amino acid, preferably an amino acid with a polar and 
       charged side chain, most preferably aspartic acid or glutamic 
       acid

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is an amino acid, preferably an amino acid with an aromatic 
       and uncharged moiety in the side chain, most preferably 
       phenylalanine or tyrosine

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa is an amino acid, preferably an amino acid with a charged 
       side chain, most preferably aspartic acid or glutamic acid

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa is an amino acid, preferably an amino acid with a non-polar 
       and a hydrophobic side chain, most preferably leucine or 
       tryptophan

<400>  2

Xaa Xaa Cys Val Glu Val Xaa Gln Asn Ser Cys Xaa Xaa 
1               5                   10              


<210>  3
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic oligopeptide

<400>  3

Leu Asp Cys Val Glu Val Phe Gln Asn Ser Cys Asp Trp 
1               5                   10              


<210>  4
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic oligopeptide

<400>  4

Ser Glu Cys Val Glu Val Phe Gln Asn Ser Cys Asp Trp 
1               5                   10              


<210>  5
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic oligopeptide

<400>  5

Ser Asp Cys Val Glu Val Phe Gln Asn Ser Cys Asp Trp 
1               5                   10              


<210>  6
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic oligopeptide

<400>  6

Leu Glu Cys Val Glu Val Tyr Gln Asn Ser Cys Glu Trp 
1               5                   10              


<210>  7
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic oligopeptide

<400>  7

Ser Glu Cys Val Glu Val Phe Gln Asn Ser Cys Glu Leu 
1               5                   10              


<210>  8
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic oligopeptide

<400>  8

Ser Asp Cys Val Glu Val Tyr Gln Asn Ser Cys Asp Trp 
1               5                   10              


<210>  9
<211>  4
<212>  PRT
<213>  Artificial

<220>
<223>  Protease cleavage site


<220>
<221>  MISC_FEATURE
<222>  (1)..(4)
<223>  Protease cleavage site

<400>  9

Ile Glu Gly Arg 
1               


<210>  10
<211>  5
<212>  PRT
<213>  Artificial

<220>
<223>  DDDDK


<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Protease cleavage site

<400>  10

Asp Asp Asp Asp Lys 
1               5   


<210>  11
<211>  6
<212>  PRT
<213>  Artificial

<220>
<223>  LVPRGS


<220>
<221>  MISC_FEATURE
<222>  (1)..(6)
<223>  Protease cleavage site

<400>  11

Leu Val Pro Arg Gly Ser 
1               5       


<210>  12
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  ENLYFQG


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  Protease cleavage site

<400>  12

Glu Asn Leu Tyr Phe Gln Gly 
1               5           


<210>  13
<211>  8
<212>  PRT
<213>  Artificial

<220>
<223>  Protease cleavage site


<220>
<221>  MISC_FEATURE
<222>  (1)..(8)
<223>  Protease cleavage site

<400>  13

Leu Glu Val Leu Phe Gln Gly Pro 
1               5               


